Diamedica Therapeutics Inc DMAC

$9.52 -0.30 (-3.05%)

Valuation

Market cap
529,553,000
Revenue TTM
$0
Net income TTM
$-32,770,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
196,500
Avg volume
197,822
Day's range
$9.41 – $9.99
Shares out
53,926,000
Stochastic %K
76%
Beta
0.92
Analysts
Strong Sell
Price target
$15.50

Price

Company profile

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal g...

Show more

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Industry
Biotechnology
Sector
Healthcare
Phone
763 496 5454
Website
https://www.diamedica.com
Address
301 Carlson Parkway, Suite 210, Minneapolis, United States

Latest news

Stocktwits

Danger_Will_Robinson Oct 29, 1:28 PM
$DMAC will today be the day …
0 replies
Tjcmd Oct 29, 5:13 AM
$DMAC I like management. This was a drug to treat acute ischemic stroke…ok…but then pivoted to a much larger TAM…pre-eclampsia and then fetal growth retardation…nimble and smart
0 replies
Stock_picker_trader Oct 29, 2:57 AM
$DMAC I wonder if the movement was the rat toxicity study being completed and they are now ready to submit the IND to the FDA to start up the phase 2 in the United States
0 replies
JMforProfits Oct 28, 7:20 PM
$DMAC I couldn’t find any news to trigger the increase today. Anybody know why the move today?
1 replies
Sicksir Oct 28, 3:52 PM
$DMAC Smart money pouring in.
1 replies
Van_Buren_Boyz Oct 28, 3:43 PM
$DMAC Key Short Interest Metrics Current Short Interest: ~5.24 million shares Short Percent of Float: ~10.23% Short Interest Ratio (Days to Cover): ~21.6 days Dollar Volume Sold Short: ~$42.14 million Change from Previous Period: Down -6.08% (from 5.58M shares in late September)
0 replies
Van_Buren_Boyz Oct 28, 3:41 PM
$DMAC early volume looks good. Ofc, someone knows something but what is it?
0 replies
Danger_Will_Robinson Oct 28, 2:53 PM
$DMAC … feeling good looking good Billy Ray!
0 replies